Get 40% Off
🚀 Our AI Picked 6 Stocks that Jumped +25% in Q1. Which Picks Will Soar in Q2?Unlock full list

Judge trims US lawsuit accusing Cencora of fueling opioid epidemic

Published 11/06/2023, 05:43 PM
Updated 11/06/2023, 06:10 PM
© Reuters. FILE PHOTO: SENSITIVE MATERIAL. THIS IMAGE MAY OFFEND OR DISTURB    A drug consumer injects a mixture of the opioid fentanyl and heroin at Richman (Echo) Park in the Bronx borough of New York City, U.S., July 20, 2023.  REUTERS/Shannon Stapleton/File Phot

By Brendan Pierson

(Reuters) - A federal judge on Monday pared back a U.S. government lawsuit accusing drug distributor Cencora, formerly called AmerisourceBergen (NYSE:COR), of fueling the nation's deadly opioid epidemic by failing to report hundreds of thousands of suspicious orders of prescription painkillers.

U.S. District Judge Jerry Pappert in Philadelphia federal court ruled that the government could only seek penalties for alleged failure to report suspicious orders after October 2018, when the federal Controlled Substances Act was amended to explicitly require such reports. The government's lawsuit, filed last December, claimed that the company failed to report suspicious orders going back to 2014.

It was not immediately clear how large an effect the order could have on Cencora's potential liability in the case. The U.S. Department of Justice declined to comment, and Cencora did not immediately respond to a request for comment.

The government claimed in its lawsuit that Cencora systematically refused or negligently failed to flag suspicious orders by pharmacy customers when it had reason to know that opioids were being diverted to illegal channels.

It also said the Conshohocken, Pennsylvania-based company, which reported $238.6 billion of revenue in its latest fiscal year, intentionally altered how one of its units monitored orders, dramatically reducing the number that underwent internal scrutiny.

The company in December called allegations in the lawsuit "cherry-picked" and said the government was seeking to "shift blame" away from law enforcement failures.

Opioids, including prescription painkillers and illegal narcotics, have contributed to more than 564,000 overdose deaths from 1999 to 2020, including more than 68,000 in 2020 alone, according to U.S. government data. Litigation by state and local governments has resulted in settlements with drugmakers, distributors, including Cencora, and pharmacies worth more than $50 billion.

© Reuters. FILE PHOTO: SENSITIVE MATERIAL. THIS IMAGE MAY OFFEND OR DISTURB    A drug consumer injects a mixture of the opioid fentanyl and heroin at Richman (Echo) Park in the Bronx borough of New York City, U.S., July 20, 2023.  REUTERS/Shannon Stapleton/File Photo

The nation's other two largest drug distributors, McKesson (NYSE:MCK) and Cardinal Health (NYSE:CAH), have reached settlements with the government over similar allegations for $150 million and $44 million. Those cases were limited to orders in a handful of states, while the lawsuit against Cencora involves much broader claims.

Cencora announced its name change in January.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.